AUS
NZ
UK
CA
USA
IND
Highlights:
- First Human Dosing of IMP761: Immutep (ASX:IMM) has initiated its first human trial for IMP761, a new autoimmune treatment based on LAG-3, aiming to modulate malfunctioning T cells associated with autoimmune diseases.
- Targeted Autoimmune Conditions: IMP761 is designed to specifically silence autoimmune memory T cells at disease sites, with potential applications in rheumatoid arthritis, type 1 diabetes, and multiple sclerosis.
- Phase I Trial Details: The Phase I study, involving 49 volunteers, is being conducted at the Dutch Centre for Human Drug Research (CHDR) in Leiden. Safety data from this trial will be closely monitored, with preliminary results expected in the first half of next year.
Immutep (ASX:IMM) has announced that it has dosed the first human patient with IMP761, a promising drug candidate targeting autoimmune diseases. IMP761 is based on LAG-3 (Lymphocyte Activation Gene 3), a molecule believed to modulate T cells involved in various autoimmune conditions.
LAG-3 is thought to address issues with malfunctioning T cells, which are implicated in many autoimmune disorders, including rheumatoid arthritis, type 1 diabetes, and multiple sclerosis. IMP761 aims to specifically target and silence autoimmune memory T cells that gather at disease sites.
The Phase I clinical trial, conducted at the Dutch Centre for Human Drug Research (CHDR) in Leiden, will involve 49 volunteers. Given that this is the first human trial for IMP761, the company will closely monitor safety data, with preliminary results expected to be available in the first half of next year.
While the primary focus is on autoimmune conditions, the use of LAG-3 in cancer immunotherapy has also been explored in existing research.
